[{"address1": "19 Vestry Street", "city": "New York", "state": "NY", "zip": "10013", "country": "United States", "website": "https://brightmindsbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Ian  McDonald", "age": 34, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1989, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan E. S. K. Cheung B.Com., CA, CPA", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 89226, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan Torleif Pedersen M.Sc., Ph.D.", "age": 58, "title": "Chief Science Officer & Director", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 181092, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark A. Smith M.D., Ph.D.", "age": 68, "title": "Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 243539, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Emer  Leahy M.B.A., Ph.D.", "age": 56, "title": "Consultant", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.04, "open": 1.075, "dayLow": 1.04, "dayHigh": 1.075, "regularMarketPreviousClose": 1.04, "regularMarketOpen": 1.075, "regularMarketDayLow": 1.04, "regularMarketDayHigh": 1.075, "beta": 1.688, "volume": 24689, "regularMarketVolume": 24689, "averageVolume": 101546, "averageVolume10days": 514760, "averageDailyVolume10Day": 514760, "marketCap": 4731670, "fiftyTwoWeekLow": 0.93, "fiftyTwoWeekHigh": 2.39, "fiftyDayAverage": 1.08944, "twoHundredDayAverage": 1.356935, "currency": "USD", "enterpriseValue": -1444560, "floatShares": 3183341, "sharesOutstanding": 4463840, "sharesShort": 72692, "sharesShortPriorMonth": 69790, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0163, "heldPercentInsiders": 0.35479, "heldPercentInstitutions": 0.04425, "shortRatio": 1.72, "shortPercentOfFloat": 0.020299999, "bookValue": 1.366, "priceToBook": 0.7759882, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -3580629, "trailingEps": -0.65, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "DRUG", "underlyingSymbol": "DRUG", "shortName": "Bright Minds Biosciences Inc.", "longName": "Bright Minds Biosciences Inc.", "firstTradeDateEpochUtc": 1616419800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "7de90f41-6566-3a5c-a990-c3e8fec46e3b", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.06, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 6190244, "totalCashPerShare": 1.387, "totalDebt": 14016, "quickRatio": 34.751, "currentRatio": 35.077, "debtToEquity": 0.23, "returnOnAssets": -0.28858998, "returnOnEquity": -0.51799, "freeCashflow": -1337075, "operatingCashflow": -2584540, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2024-09-01"}]